Enhancing Kidney Function Assessment: The Shift to CKD-EPI 2021 Race-Free eGFR Calculation and the Role of Cystatin C

Enhancing Kidney Function Assessment: The Shift to CKD-EPI 2021 Race-Free eGFR Calculation and the Role of Cystatin C

Chronic kidney disease (CKD) is a rising health concern globally, necessitating accurate and reliable methods for assessing kidney function. The introduction of the CKD-EPI 2021 race-free estimated glomerular filtration rate (eGFR) calculation marks a significant advancement in this area. By eliminating race from the equation, healthcare providers aim to deliver more equitable care. However, the transition to this new standard involves careful consideration of additional testing, particularly the use of cystatin C as a confirmatory test. This article will explore the implications of these developments, the importance of accurate kidney function assessments, and actionable recommendations for clinical laboratories.

The CKD-EPI 2021 race-free eGFR calculation improves upon previous formulas by offering a more precise estimate of kidney function for diverse patient populations. This method minimizes the biases that can arise from race-based calculations, providing healthcare professionals with a tool that reflects true renal function without the influence of racial factors. As a result, it aims to enhance the accuracy of CKD diagnosis and management, leading to better patient outcomes.

Despite the advancements made with the CKD-EPI 2021 calculation, there are still scenarios where creatinine levels alone may not provide a complete picture of kidney function. Clinical guidelines recommend the use of cystatin C as a confirmatory test in specific circumstances. For instance, patients with an eGFR calculated using serum creatinine (eGFRcr) between 45-59 mL/min/1.73m² and a urine albumin-to-creatinine ratio (uACR) of less than 30 mg/g may benefit from a cystatin C measurement. This is particularly important for individuals whose creatinine levels may not accurately reflect their glomerular filtration rate (GFR), such as the elderly or those with muscle mass alterations.

Incorporating cystatin C testing into routine clinical practice offers several advantages. First, cystatin C is less influenced by factors such as muscle mass, diet, and inflammation, making it a valuable tool for obtaining a clearer picture of kidney function. Moreover, eGFRcr-cys, which combines serum creatinine and cystatin C measurements, can provide a more accurate estimate of GFR, especially in borderline cases. As healthcare providers navigate the changing landscape of kidney function assessment, understanding the nuances of these tests and their indications is essential for delivering high-quality patient care.

To facilitate the effective implementation of the CKD-EPI 2021 race-free eGFR calculation and cystatin C testing, clinical laboratories can adopt the following actionable strategies: